R&D Failures Mean Lean Future, Falling Stocks for Lilly

Oct 16, 2013

ibj.com

Wall Street analysts do not have high hopes for Eli Lilly's revenue until 2020.

A string of R&D failures has left Lilly with nothing that even remotely approaches the $5 billion in annual sales of  Cymbalta, Lilly’s best-selling drug, which will see its U.S. patents expire in December.

Experts predict seven lean years for the drugmaker, in which its executives will have to focus on producing profits more through reducing expenses than growing sales. Read the full analysis.

Show Comments
Hide Comments

Join the discussion

We welcome your thoughtful comments.
All comments will display your user name.

Want to participate in the discussion?

Register for free

Log in for complete access.

Comments

No one has commented on this page yet.

RSS feed for comments on this page | RSS feed for all comments